14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CAPR vs ERAS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Erasca, Inc. (ERAS) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas ERAS carries 36.9/100 (SELL) at $14.95 (N/M Forward P/E, 0.0% operating margin).
Defensive Composite Rating Caution: Although ERAS compares more favorably head-to-head, both CAPR (28.0/100 SELL) and ERAS (36.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile ERAS is in a Breakdown options structure phase (RSI 51.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAPR vs ERAS. Trailing 12-month operating profitability (CAPR 0.0% vs ERAS 0.0%) and valuation multiples (CAPR 78.7x vs ERAS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $5.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CAPR vs ERAS Key Questions & Quantitative Answers
As of Nov 16, 2026, Erasca, Inc. (ERAS) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas ERAS carries 36.9/100 (SELL) at $14.95 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although ERAS compares more favorably head-to-head, both CAPR (28.0/100 SELL) and ERAS (36.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile ERAS is in a Breakdown options structure phase (RSI 51.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ERAS leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with ERAS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CAPR generates $11M in USD-normalized revenue versus N/A for ERAS. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ERAS.
CAPR screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas ERAS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus ERAS (-48.7% ROE) capital efficiency.
In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, ERAS carries 89.2% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.31β · 81% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.